KLF4 and acute lymphoblastic leukemia: However, in stark contrast to the aforementioned tumor types, KLF4 is consistently recognized as a tumor suppressor in GC and T‐ALL, with relatively specific mechanisms of action, providing a relatively robust preclinical rationale for therapeutic strategies targeting KLF4 [45, 46].